Abstract:ID 90764 Poster Board 476 Migraine is the most common neurological disorder in the world, and is characterized by severe headaches, nausea, and light sensitivity. Current migraine treatments, including opioids and triptans, produce dangerous and uncomfortable side effects. Moreover, modern anti-migraine drugs lack novel mechanisms of action, often resulting in side effects similar to traditional approaches. Our aim is to revolutionize migraine pain management by finding new medications with novel mechanisms that can provide relief from migraine without causing any negative side effects. Fatty acid amide hydrolase (FAAH) and soluble epoxide hydrolase (sEH) are two pain-related enzymes. The potential benefits of dual-enzyme inhibitors include fewer drug-to-drug interactions and improved drug synergism compared to the administration of just one enzyme inhibitor. Importantly, these dual inhibitors may require lower doses than the traditional anti-migraine agent, sumatriptan. We hypothesized that simultaneous inhibition of FAAH and sEH using a dual sEH/FAAH inhibitor will alleviate migraine-related pain in rats. We previously identified a potent dual inhibitor SW-17 with IC 50 values of 9.8 nM and 2.5 nM in human FAAH and human sEH enzymes, respectively. Interestingly, SW-17 was significantly less active in mouse sEH, but was very potent in rat sEH with IC50 value of 3.9 nM. In this study, we synthesized 19 follow-up analogs of SW-17 to test the importance of the sulfonamide group. After evaluation of their potencies at inhibiting human, mouse, and rat enzymes, it appears that SW-17 is the most potent dual inhibitor; therefore, SW-17 was scaled up and evaluated in vivo . In migraineurs, an injection of nitroglycerin typically triggers a migraine attack, which makes it a useful tool to generate headache-like pain in animals. An injection of nitroglycerin produces hypersensitivity in periorbital and hindpaw regions. Thus, we investigated the effects of various doses of dual inhibitors of sEH and FAAH in a rat model of nitroglycerin-induced pain to assess its efficacy. To induce migraine pain, we injected 10 mg/kg nitroglycerin, a vasodilator that induces migraine-like pain. Thirty minutes prior to the injection of nitroglycerin, we pre-treated rats with a dose of SW-17, the sEH/FAAH dual inhibitor, in varying doses (0.1, 0.3, and 1 mg/kg) or sumatriptan. Mechanical thresholds in the hindpaw were assessed 30, 60, and 120 minutes after nitroglycerin injection. A nitroglycerin injection lowered sensory thresholds in female rats indicating migraine-like pain. A pre-treatment of SW-17 and sumatriptan prevented nitroglycerin-induced decreases in mechanical hypersensitivity. Finally, a wheel running test indicated that SW-17 does not decrease voluntary activity in rats indicating that this drug may not produce motoric side effects. Future studies will determine the full efficacy of FAAH and sEH inhibition in alleviating migraine-like pain in rats. Funded by NIH grant R16 GM150781 and CSUBIOTECH.

Effects of peripheral FAAH blockade on NTG-induced hyperalgesia—evaluation of URB937 in an animal model of migraine

Activation of CB2 receptors as a potential therapeutic target for migraine: evaluation in an animal model

Effects of CGRP receptor antagonism in nitroglycerin-induced hyperalgesia

Effects of the Dual FAAH/MAGL Inhibitor AKU-005 on Trigeminal Hyperalgesia in Male Rats

Dual Inhibition of FAAH and MAGL Counteracts Migraine-like Pain and Behavior in an Animal Model of Migraine

Inhibition of FAAH reduces nitroglycerin-induced migraine-like pain and trigeminal neuronal hyperactivity in mice

Dimethyl fumarate alleviates the nitroglycerin (NTG)-induced migraine in mice

Effect of BAY‐117082, a NLRP3 inflammasome inhibitor, in a mouse model of nitroglycerin (NTG)‐induced migraine

Ghrelin attenuated hyperalgesia induced by chronic nitroglycerin: CGRP and TRPV1 as targets for migraine management

Chronic and intermittent administration of systemic nitroglycerin in the rat induces an increase in the gene expression of CGRP in central areas: potential contribution to pain processing

Supplementation with SCFAs Re-Establishes Microbiota Composition and Attenuates Hyperalgesia and Pain in a Mouse Model of NTG-Induced Migraine

The role of the transient receptor potential ankyrin type-1 (TRPA1) channel in migraine pain: evaluation in an animal model

IL-17 crosses the blood–brain barrier to trigger neuroinflammation: a novel mechanism in nitroglycerin-induced chronic migraine

The role of basolateral amygdala orexin 1 receptors on the modulation of pain and psychosocial deficits in nitroglycerin-induced migraine model in adult male rats

Brain-wide mapping of c-Fos expression in nitroglycerin-induced models of migraine

Sumatriptan alleviates nitroglycerin-induced mechanical and thermal allodynia in mice

NOP receptor agonist attenuates nitroglycerin-induced migraine-like symptoms in mice

The Analgesic Effects of (5R,6R)6-(3-Propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1] Octane on a Mouse Model of Neuropathic Pain.

Simultaneous Inhibition of Soluble Epoxide Hydrolase and Fatty Acid Amide Hydrolase Prevents Nitroglycerin-induced Hypersensitivity in Female Rats

Utility of different outcome measures for the nitroglycerin model of migraine in mice

Fenofibrate ameliorates nitroglycerin-induced migraine in rats: Role of CGRP/p-CREB/P2X3 and NGF/PKC/ASIC3 signaling pathways